Subretinal fibrosis in patients with Vogt-Koyanagi-Harada disease

被引:47
|
作者
Kuo, IC
Rechdouni, A
Rao, NA
Johnston, RH
Margolis, TP
Cunningham, ET [1 ]
机构
[1] Univ Calif San Francisco, Med Ctr, Francis I Proctor Fdn, Pearl & Samuel J Kimura Ocular Immunol Lab, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Dept Ophthalmol, San Francisco, CA 94143 USA
[3] Univ So Calif, Keck Sch Med, Dept Ophthalmol, Los Angeles, CA USA
[4] Univ So Calif, Doheny Eye Inst, Los Angeles, CA USA
关键词
D O I
10.1016/S0161-6420(00)00244-X
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Objectives To describe subretinal fibrosis as a long-term complication of Vogt-Koyanagi-Harada (VKH) disease. Design: Retrospective, clinic-based, cross-sectional study and clinical correlation. Participants: Ten patients with VKH disease and subretinal fibrosis were seen at two uveitis referral centers between 1977 and 1997. Interventions A review of the historical, clinical, and fluorescein angiographic features was performed. Main Outcome Measures: The prevalence, demographic and clinical features, and time to development of subretinal fibrosis were summarized. Results: Subretinal fibrosis occurred in 20 eyes of 10 patients with VKH disease, an overall prevalence of 8% between the two institutions. Patient age ranged from 16 years to 48 years, with a median of 34.5 years. Five patients were Hispanic, one was mixed Hispanic and American Indian, three were Asian or mixed Asian and Caucasian, and one was African-American. Eight of the 10 patients were men. All patients were in the chronic, recurrent phase of their disease when they had subretinal fibrosis develop, and all patients had recurrent episodes of posterior uveitis. Presenting vision ranged from 20/20 to light perception, with a median acuity of 20/200. All patients were initially treated with oral and topical corticosteroids. Four patients required additional noncorticosteroid immunosuppressive therapy. Time from diagnosis of VKH disease to development of subretinal fibrosis ranged from zero (fibrosis present at time of diagnosis) to 27 years, with a median time of 10 months. The median time from diagnosis of VKH to development of subretinal fibrosis in Hispanic patients was 6.5 months, whereas in non-Hispanic patients it was 6.5 years. Final vision ranged from 20/25 to light perception, with a median acuity of 20/60. Seven of 20 eyes had a final visual acuity of 20/40 or better, and seven eyes saw 20/200 or worse. Five of the eyes with 20/200 or worse vision had fibrosis involving the fovea. Conclusions: Subretinal fibrosis occurs in a sizeable proportion of patients with VKH disease and may contribute to permanent loss of vision. Ophthalmology 2000;107:1721-1728 (C) 2000 by the American Academy of Ophthalmology.
引用
收藏
页码:1721 / 1728
页数:8
相关论文
共 50 条
  • [21] Vogt-Koyanagi-Harada disease in hispanic patients
    Sukavatcharin S.
    Tsai J.H.
    Rao N.A.
    International Ophthalmology, 2007, 27 (2-3) : 143 - 148
  • [22] Subretinal fibrosis as a long-term complication of Vogt-Koyanagi-Harada syndrome
    Kuo, IC
    Rao, NA
    Johnston, R
    Margolis, TP
    Nozik, RA
    Cunningham, ET
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 1999, 40 (04) : S383 - S383
  • [23] SUBRETINAL NEOVASCULAR MEMBRANES IN VOGT-KOYANAGI-HARADA SYNDROME
    MOORTHY, RS
    CHONG, LP
    SMITH, RE
    RAO, NA
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 1993, 34 (04) : 1105 - 1105
  • [24] SUBRETINAL NEOVASCULAR MEMBRANES IN VOGT-KOYANAGI-HARADA SYNDROME
    MOORTHY, RS
    CHONG, LP
    SMITH, RE
    RAO, NA
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 1993, 116 (02) : 164 - 170
  • [25] Tofacitinib in Vogt-Koyanagi-Harada disease
    Majumder, Parthopratim Dutta
    Shah, Amravi
    Kaushik, Viswanath
    INDIAN JOURNAL OF OPHTHALMOLOGY, 2020, 68 (09) : 1938 - 1939
  • [26] Vogt-Koyanagi-Harada Disease and COVID
    Manni, Priscilla
    Saturno, Maria Carmela
    Accorinti, Massimo
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (19)
  • [27] Vogt-Koyanagi-Harada disease in children
    Abu El-Asrar, A. M.
    Al-Kharashi, A. S.
    Aldibhi, H.
    Al-Fraykh, H.
    Kangave, D.
    EYE, 2008, 22 (09) : 1124 - 1131
  • [28] Vogt-Koyanagi-Harada disease in children
    A M Abu El-Asrar
    A S Al-Kharashi
    H Aldibhi
    H Al-Fraykh
    D Kangave
    Eye, 2008, 22 : 1124 - 1131
  • [29] Pathology of Vogt-Koyanagi-Harada disease
    Rao N.A.
    International Ophthalmology, 2007, 27 (2-3) : 81 - 85
  • [30] HLA AND VOGT-KOYANAGI-HARADA DISEASE
    OHNO, S
    ACTA OPHTHALMOLOGICA, 1984, : 46 - 49